DES IGF-1

DES IGF-1 acts primarily as an agonist of the IGF-1 receptor (IGF-1R). By lacking the first three amino acids, it binds weakly to IGFBPs, allowing greater availability to interact with the receptor. Binding to IGF-1R triggers receptor autophosphorylation and activation of key intracellular signaling pathways:

• PI3K/Akt pathway: promotes cell survival, protein synthesis, and inhibition of apoptosis.
• MAPK/ERK pathway: stimulates cell proliferation and differentiation.
• Glucose transport: increases glucose uptake in muscle and adipose cells, similar to insulin but with a weaker hypoglycemic effect.

• Muscle growth research: used to study hypertrophy and muscle regeneration in animal models.
• Cell signaling studies: a tool to investigate the IGF-1R pathway and its effects on cell proliferation and differentiation.
• Disease models: employed in research on cancer, diabetes, and growth disorders.

The effects of DES IGF-1 in experimental studies include increased muscle protein synthesis, promotion of hypertrophy, enhanced tissue regeneration, and possible stimulation of cell proliferation. Due to its low binding to IGFBPs, its effects are faster and more potent than those of native IGF-1. However, its use is not without risks, such as potential promotion of tumor growth in susceptible models.

DES IGF-1 is a research compound and should not be used in humans outside of authorized clinical trials. Key considerations include:

• Risk of hypoglycemia: although less than insulin, it can cause decreases in glucose levels.
• Mitogenic potential: may stimulate the proliferation of cancer cells.
• Adverse effects: possible injection site reactions, joint pain, and edema.
• Contraindications: should not be used in the presence of active neoplasms, diabetic retinopathy, or during pregnancy.

DES IGF-1 is not approved by any regulatory agency (FDA, EMA, etc.) for clinical use in humans. It is used exclusively as a research tool in laboratories and preclinical studies. There is no commercial drug based on this peptide.

There is no standard dosage for humans due to its research status. In animal studies, typical doses range from 10-100 µg/kg/day subcutaneously. In cell culture, it is used at concentrations of 1-100 ng/mL. Its use is not recommended without expert supervision.

Lyophilized DES IGF-1 should be stored at -20°C, protected from light and moisture. Once reconstituted in sterile water or saline, it is recommended to keep it at 2-8°C and use within 7-14 days. Do not freeze after reconstitution. Avoid repeated freeze-thaw cycles.